What are the ASCO guidelines for the pharmacologic reduction of breast cancer risk?

Updated: Dec 27, 2019
  • Author: Pavani Chalasani, MD, MPH; Chief Editor: John V Kiluk, MD, FACS  more...
  • Print

ASCO guidelines recommend the following [166] :

  • For premenopausal or postmenopausal women with increased risk for breast cancer, offer tamoxifen (20 mg/day for 5 years) to reduce the risk of invasive ER-positive breast cancer

  • In postmenopausal women, raloxifene (60 mg/day for 5 years) may also be considered

  • Off-label use of exemestane (25 mg/day for 5 years) should be discussed as an alternative to reduce the risk in postmenopausal women

  • All 3 agents should be discussed (including risks and benefits) with women aged 35 years or older without a personal history of breast cancer who are at increased risk of developing invasive breast cancer

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!